NOVEL ANTIBACTERIAL PEPTIDE AND USE THEREOF
The present invention refers to novel anti-microbial peptide and use thereof relates to search, more specifically the activity of immuno-bypass novel peptide and its use with control function are disclosed. Anti-microbial peptide film contains thermoplastic synthetic peptide found in airway from active and may appear as follows. The anti-microbial peptide include impersonal compared proteins for a relatively short comprises the amino acid sequence (10 to 100 reliant reliant) consists, mainly the membrane 1) intended to inhibit or block the energy production of the microorganism via the ion channel, 2) is equal to a large hole intended to cause the production of a cell resulting lethal. The physically destroy microorganisms is, unlike existing antibiotics inhibiting intracellular or cell wall of microorganisms polymer synthesizing number for an area have developed resistance to anti-microbial peptide microorganisms are very difficult, which has been generated from a plasma current deep resistance. Many anti-microbial peptide sequence of temporal similarity between known do not appear but generally, several general tendency of active aspects of structure and exhibit other. Typically anti-microbial peptide lysine, arginine, histidine and hydrophobic portion such as a positively charged with that portion is found mote [tin[tin] with are disclosed. In the future when the number most hypotheses related to current anti-microbial peptide of anbiotics (SMH) model such that the features of the sequence of anti-microbial peptide in and Shai provided Matsuzaki non-Huang and functional groups described as follows and before 2000: a positively charged hydrophilic portion combined with negatively charged after bacterial cell membranes, the membranes and coupled hydrophobic portion (phospholipid) interacts with the hydrophobic moiety of membrane phospholipids agents, cell membranes to form hole on the plasma membrane of cells is connected to the crushed by permeability to be coated. Neutrophil (neutrophil) and mono-site (phagocytic cell) such as formyl peptide receptor expressed in phagocytic group (formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)) used for the pathogen of the host against infection (defense) plays an important role in (Mangmool, S. The present invention refers to said door such as number points to solve various door number points is provided, having an antibacterial action more efficient immune activity intended for the peptide under public affairs number. While the present invention refers to, said antimicrobial peptide including number, pharmaceutical compositions for treating atopic dermatitis, and atopic skin cosmetic compositions or the like said under public affairs intended for a variety of uses the number of the peptide. Example number is however and generally, the range of the present invention is defined in which are not correct. Another of the present invention in one aspect, the sequence numbers 1 amino acid sequences encoded novel antibacterial and immunomodulatory peptides is ball number. Another of the present invention in one aspect, said peptide active ingredient including antimicrobial number is encoded ball number. Another selectively implanted into the of the present invention, said medicinal compositions for treating atopic dermatitis including ball number encoded peptide active ingredient. Another of the present invention in one aspect, said peptide active ingredient including atopic dermatitis cosmetic composition applied ball number. In the embodiment according to Figure 1 of the present invention has an amino acid sequence sequence number written in one end roh diary agents added N - preparation of 1 gram ( Definition of terms: The terms used in this document to define such as disclosed. The term "immunomodulatory peptides" is used in this document while non-immunoglobulin protein directly or indirectly and has antibacterial and antiviral action, inflammation reaction control, natural killer cell stimulation, such as immune response action by big peptide control antibody dependent cellular cytotoxicity. Different meanings include decryption by said gene (neutrophil) and mono-site (phagocytic cell) such as neutrophil proteins are expressed in formyl peptide receptor on phagocytic group (formyl peptide receptor 1 (FPR1) and formyl peptide receptor 2 (FPR2)) (defense) against pathogen infection of the host with significant could be bonded each other. Said receptors toxoids as signal - sensitive (pertussis toxin a-sensitive) adsorbents Gi proteins known. FPR1 and FPR2 G β γ subunit induce separation of activation of the G α i subunit, the number C β or phosphoinositide 3 - kinase gun [su[su] gun group β γ - subunit or number of activation substrate. Activating the lower (downstream) signaling complex such molecules by inducing chemotaxis mobile (chemotactic migration), the degranulation (degranulation), and a super oxide generating (superoxide generation) cellular response such as various as follows. This document the term "anti-microbial peptide" used in relatively simple structure is cationic peptide in a conventional gram (cationic peptide) compound (gram-a positive bacteria), gram-negative bacteria (gram-a negative bacteria), fungi, viruses such as for broad antibacterial spectrum and that is, the megakaryocyte cell membranes of microorganisms generally but not completely mechanisms destroy activity through mechanisms of action that represents an known. Used in this document the term "atopic dermatitis" pediatric inflammatory skin disease in most infants and the surrounding feeling severe itching, carbostyril derivatives for, edema, leach, blood, acids, characterized like planus, and to a position where a recurrence due to repetitive chemical formula 2 or the like planus with scratch elapsed and chronic sofa a lesion that is shown therein. Detailed description of the invention: Hereinafter the present invention more detailed the on-sensors other. Another of the present invention in one aspect, the sequence numbers 1 amino acid sequences encoded novel antibacterial and immunomodulatory peptides is ball number. N - end peptide preparation of said furnace diary (octanoyl group, CH3 (CH2 )6 CO -, hereinafter 'Oct -' to the accumulated code length) and may be with, the amino acid can be added C - end 1 to 6. Another of the present invention in one aspect, said peptide active ingredient including antimicrobial number is encoded ball number. Said antimicrobial number may have antimicrobial activity against gram-negative bacteria and a gram-positive bacteria, gram-negative bacteria is Escherichia coli said ( Another of the present invention in one aspect, the active ingredient said peptide encoded medicinal compositions for treating atopic dermatitis including ball number. Pharmaceutical compositions unexpectedly give rise said peptide active ingredient including saline, buffer saline, dextrose, water, glycerol and pharmaceutical dilution number 1 can be selected from at least one of ethanol comprising, dilution number is limited to are not correct. Administering said pharmaceutical compositions according hereinafter can be applied on the aim and disease. The amount of active ingredient administered substantially various associated elements, i.e. diseases in the treatment, the degree of patient, other (e.g. chemotaxis about number) on whether co-administering about number, sex of a patient age, body weight, food, administration time, routes, and taking into account the administration of ratio (ratio) determine whether the other. Said composition can be adjusted according to the type and severity of the disease and dosages and routes but once per day can be administered once or divided into 1 - 3. Of the present invention can be administered as a peptide or a substance including oral or parenteral composition. Other than oral parenteral administration routes, i.e. rectal, intravenous, peritoneal and muscle, artery, transdermal, nasal (nasal), inhalation, ocular, and under blood about through big number administration. Said peptide or a substance including pharmaceutical compositions include oral dosage forms, such as injectable solution or topical number number number number as any type of 1308. Number number oral and injection dosage (battle array (true solution) solution, suspension or emulsion) of suitable preferably tank and to number, positive number, capsule, soft capsule, aqueous about number, ring number, number bath preferably oral form granules such as best. Excipient (excipient) number in said number number of peptide of the present invention soft capsule without filling, or in admixture with a suitable number number made to supported after dilution. Examples of suitable carrier starch, water, saline, ringer's solution, dextrose etc.. Another of the present invention in one aspect, atopic skin cosmetic composition including said peptide encoded ball number. Said cosmetic composition comprising at least one cosmetic composition number type addition of number can be used. For example, such number is added 1, 3 - it will send, [leyn[leyn] glycol, soybean phospholipid choline, sphingosine, cholesterol, twin 80, a factor, salicylic acid, skin moisturizing number (wet number), flexible number, natural oils, keratin, synchronized liposomes, absorbing a water-soluble substance, stratum corneum ceramide, skin lipid acidic membrane fatty acid, cholesteryl ester, ethanol, can be distilled water or the like as possible. Hereinafter, embodiments of the present invention refers to in the embodiment described and detailed further through the experiment. However the present invention refers to hereinafter disclosure in the embodiment but different in the embodiment and experiments defined in various forms can also be implemented in the event that, in the embodiment of the present invention disclosure is completely and experiments of such embodiments hereinafter, for alerting the person with skill in the art of the invention completely categories to which ball number are disclosed. In the embodiment 1: anti-microbial peptide of number bath The present invention based on the victims of the sequence numbers 1 through screening having antibacterial activity peptide consisting of amino acid sequences (KFKWRYm) written in his search. Said peptide is a conventional amino acid synthesis (Umbarger, H. E. , In the embodiment 2: formulae of anti-microbial peptide The present invention searches for the victims of the agents in order to improve the antimicrobial activity than at said in the embodiment 1, palmitate earth diary, such as lipid components of the peptide N - end attached to said furnace diary preparation of modified peptide by combining, antimicrobial activity visit from the police. As a result, modified peptides may be identified as the most active member of the attached roh diary preparation of a good shape, in an alternative embodiment a peptide (hereinafter, 'NCP112' inhibits cellular) Oct-a KFKWRYm after experiment was used. In the embodiment 1: novel peptide antimicrobial activity experiments In antimicrobial activity of the peptide prepared by the number said in the embodiment 2 for measuring anti-microbial inspection by dielectrophoresis. Gram ( As a result, as shown in Figure 1, in the embodiment according to the peptide of the present invention antimicrobial activity against all test concentration dependent in mistletoe. In particular 10 μm in number with respect to the concentration of the growth of nine fungi you completely billion. You nine fungi of Pseudomonas ( In the embodiment 2: FPRL1Through Intracellular The ions Ca analysis The present invention peptides of the present invention activate the victims of the one in the embodiment according to said ear in order to identify the living body immune function to determine whether the observed changes in calcium ion permeable. In order to identify whether FPR2 said specifically binding peptides which activate an intracellular calcium concentration of ions were measured. To this end FPR2 RBL cells not expressing RBL FPR1 organic material in a colon cancer cells using organic material on overexpression of FPR2 (FPR1 provided RBL) cells (FPR2 provided RBL) have, glass making the measuring intracellular calcium ion can be in the packing insertion method to dyeing material Fura-a 2/AM calcium by water. I.e., the medium for culturing cells containing 10% serum RPMI right [thay[thay] when log (mid-a log phase, 1 - 3 × 107 Cells/ml) serum is free of medium RPMI right [thay[thay] harvesting centrifuging and then washed and useful as same 1 × 107 Cells/ml RPMI-gate suspended in that medium. Then adding water to the final concentration of 3 μm Fura-a 2/AM 37 °C, 5% CO2 In 45 minutes with stirring extraction continue him as. Then harvest cells useful as cleaning RPMI medium back to proper time period has lapsed then gets drawn into the same concentration of 250 μm is filled with index matching medium by cells suspended in RPMI the opinion pin blooms the zone Fura provided 2 cellular especially outside was not applied. About 2 × 106 Taken every two cells of rapid centrifugation without added calcium ion added to harvest it EGTA (Locke) 340 nm and 380 nm on spectrophotometer is suspended in 1 ml solution lock two wavelengths absorbance ratio monitoring but, in the embodiment according to one of the present invention about 1 minutes intervals different peptide concentration (1 μm, 0. 1 μm and 0. 01 μm) in two wavelengths is irradiated after processing have absorbance difference, according to the method of same green in height [wik[wik] (Grynkiewicz) later in terms of his glass calcium concentration of ions into cells. The result is as shown in the variation 2 also, in the embodiment according to of the present invention treating an intracellular calcium ion FPR2 provided RBL cells specifically only one peptide is abruptly increased (A), the amount of intracellular concentration of calcium ion concentration dependent peptide processing according to aspects mistletoe (B). This, in the embodiment according to individual peptides of the present invention combine and activation FPR2 immune function in a storehouse for clinical use are disclosed. Experiment example 3: improving effect in atopic dermatitis model 3 - 1: appearance changes analysis , the victims of the present invention of the present invention the thread number one in the embodiment according to said peptide in vivo activate immune function in order to identify whether the treating immune related diseases, atopic animal model of atopic dermatitis said peptide processing condition whether a visit from the police. Specifically inventor are capsaicin induced dermatitis in the model in order to identify whether an improvement effect of atopic dermatitis, atopic model animal in a peptide of the present invention (NCP112) one in the embodiment according to atopy induced skin tissue (Neo-a Cap and 2 W Cap) dermis, the buildup of dermis after processing degree's application region and areas are observed. The assay such as a 50 mg/kg (Sprague Dawley rat) 48 hours whether said Neo-a Cap house mouse pork skin of atopic dermatitis is atopic dermatitis improving by hypodermic injection agent of the representative model animal are disclosed. The myelin basic protein 2 to 25 mg/kg to 2 times 2 W Cap house mouse needleless hypodermic injection of agent adjusts the main improving model animal as atopic dermatitis, atopic dermatitis Mocks the model young people or adult onset are disclosed. In a specific experiment 3 treatment process is also indicated by the disclosed. In Neo-a Cap model after dermatitis score measuring behind main capsaicin scanning 2, controls (PBS) at a concentration of 10 μm and a like NCP112 daily (200 μl) and both ear (50 μl) 1 weeks intervals during dermatitis score application main 3 were measured. Dermatitis score face, ear, such as stimulated (total), such as skin (application site) have measuring state score, score is a starting point in a 2 by 1 week, shown but also 4, table 1 for the criteria such as disclosed. In capsaicin scanning 1 after dermatitis score measuring 2W provided Cap model behind main, controls (PBS) at a concentration of 10 μm and a like NCP112 daily (200 μl) and both ear (50 μl) 1 2 weeks intervals during application such as a dermatitis score Neo-a Cap main model were measured. Also shown is a starting point in the score by 3w 1 to 4. 3 - 2: evaluation of atopic dermatitis skin tissue pathologies and thickness In the embodiment according to example 3 - 1 of the present invention analyzing said mouse experiments in one main after capsaicin by the dermatitis is induced sacrificial sufficiently peptide processing 5 parts of 3 × 3 cm from the outer discharge portion an aqueous 4% paraformaldehyde solution 2 ∼ 3 one day after extraction skin tissue was fixed. 1 × 0 again fixed tissue. Size of 5 cm (Leica microsystems, Germany) are included in the tissue cassette for subdividing back to Tissue processor to dehydration, transparent, paraffin was installed application via -20 °C validation process. In order to 5 micro m (Leica microsystems, Germany) pak paragraph Microtome paraffin block 16 has a thickness of thin ribbon which has been toasted tissue after the automatic tank and connects a flat after tissue cutting after 40 °C heating plate is attached to the fragment of a slide glass was dried. Mouse dermal tissue for pathological evaluation to turn the bell 3 3 70 to 100% xylene dermal tissue fragments respectively 1 and immersing the bell and a dewaxing to flush with an ethanol solution of cells tissue immersed in order finally distilled the [hey[hey] E [thok[thok] it was recorded applicable to distilled water and dark portions of the channel it came cytoplasm was dyeing. In order to 70 to 100% ethanol dyeing tissue dewaxing process goes finally formed in a reversal of xylene (embedding reagent) number is applied after the glass covers was sealed. Optical microscope observation magnification of 200 × dyed tissue for pathological evaluation mode was. Figure 5 shows a part of the dermal tissue state according to a lapse of time also photographs and caused atopic dermatitis, atopic dermatitis is induced skin tissue parts of the 6 representing the result in electron optical tissue dyeing, Neo-a Cap and 2 W Cap group so as to both controls are typical symptoms of atopic dermatitis representing but is losing its epithelial, in the case of an article of the present invention in the embodiment according to the thickness of one peptide processing group (NCP112) Neo-a Cap have slightly reduced, significantly reduces the normal levels in group 2 W Cap schedulable recovery has been confirmed that the substantially eliminated. Thus, in the embodiment according to the peptide of the present invention result in animal experiments in both the mirror surface is made atopic Neo-a Cap and 2 W Cap model, in particular 2 W Cap model animal substantially 180 degrees between the normal state thing to represented skin condition, identifying a highly efficient treatment for queue. In the embodiment described with reference to the embodiments of the present invention refers to an exemplary experiment described above and sends a but which, in the embodiment and various deformation and equally to the other person with skill in the art in if the art therefrom will understand that it is styles are discussed experiments. The technical idea of the present invention defined by appended claim of true technology protection range generated by the will. The present invention relates to a novel peptide having antibacterial effects and regulatory functions for immune cell activities, and a use thereof. The peptide of the present invention exhibits antibacterial functions against various bacteria such as gram negative bacteria and gram positive bacteria while regulating immune cell activities, thereby being useful for treating various immune diseases such as atopic dermatitis as well as diseases caused by infection by pathogenic bacteria. COPYRIGHT KIPO 2017 The sequence numbers 1 novel antibacterial and immunomodulatory peptides are amino acid sequences. According to Claim 1, preparation of N - end furnace diary (octanoyl group, CH3 (CH2 )6 CO -) is added to, peptide. According to Claim 1 or Claim 2, C - end 1 to 6 amino acid added, peptide. Number 1 active ingredient including antimicrobial peptide according to Claim 2 anti or number. According to Claim 3 peptide active ingredient including antimicrobial number. Number 1 according to Claim 2 peptide pharmaceutical composition for treating atopic dermatitis including anti or active ingredient. According to Claim 3 peptide active ingredient including pharmaceutical compositions for treating atopic dermatitis. Cosmetic composition including atopic dermatitis according to Claim 2 peptide number 1 anti or active ingredient. Cosmetic composition according to Claim 3 peptide active ingredient including atopic dermatitis. Position Score Skin conditions Face 0 Normal 1 Turn groups 2 flare hair and 3 Bleeding or ulcer lesions ear 0 Normal 1 flare 2 Bleeding 3 Ear tissue loss such as 0 Normal 1 Turn groups 2 flare hair and 3 Bleeding or ulcer lesions
